Newsroom

Download PDF Option Triggers $25 Million in Milestone Payments to AVEO MELVILLE, N.Y. & TOKYO & CAMBRIDGE, MASS., Dec 01, 2010 (BUSINESS WIRE) — OSI Pharmaceuticals, Inc., (“OSI”), which is a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., and AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced

Download PDF CAMBRIDGE, Mass., Nov 22, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the company’s management will present a company overview at several upcoming investment conferences. David Johnston, chief financial officer, is scheduled to present at the following event:

Download PDF Preclinical Data from the Company’s FGFR Antibody Program also Presented CAMBRIDGE, Mass. & BERLIN, Nov 19, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data from AVEO’s anti-RON antibody program which demonstrated the successful identification of antibodies with

Download PDF Preclinical Data Presented Demonstrates that Combining Tivozanib with Chemotherapy Regimens Inhibits Breast Tumor Growth and Prevents Development of Resistance CAMBRIDGE, Mass. & BERLIN, Nov 18, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced results from a Phase 1b clinical

Download PDF Trial to Evaluate Tivozanib in Combination with Widely-Used Oral Xeloda® in Patients with Advanced Breast and Colorectal Cancers CAMBRIDGE, Mass., Nov 16, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center

Download PDF Tivozanib Data Also Presented at Annual Chemotherapy Foundation Symposium CAMBRIDGE, Mass., Nov 10, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that new clinical data from a Phase 1b trial evaluating the company’s lead product candidate, tivozanib, a highly

Download PDF Current Financial Position Supports Expanding and Accelerating Clinical Development Plans for Tivozanib CAMBRIDGE, Mass., Nov 04, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced updated financial guidance and third quarter financial results, as well as recent developments. “During the

Download PDF AVEO to Present at Windhover’s Annual Therapeutic Area Partnerships Meeting CAMBRIDGE, Mass., Nov 03, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that its lead product candidate, tivozanib, has been selected as one of Windhover’s “2011 Top 10 Oncology